Contents

2137 The Effect of 5-Fluorouracil on DNA-Thymine Synthesis in Human Tumors.  
William H. Wolberg.

2145 The Carcinogenic Activity of Some 5-Nitrofuran Derivatives in the Rat.  

2157 Immunization of C58 Mice to Line Iβ Leukemia.  
Juey Shin Lai Lin, Nancy Huber, and William H. Murphy.

2163 Dependence of Immunity to Iβ Leukemia on an Adjuvant Effect of Immunizing Cell Preparations.  
Juey Shin Lai Lin and William H. Murphy.

2169 Studies on the Mechanism of Action of 1-β-D-Arabinofuranosylcytosine as an Inhibitor of DNA Synthesis in Human Leukemic Leukocytes.  
Akira Inigaki, Toru Nakamura, and Gyoichi Wakisaka.

2177 Immunotherapy and Chemotherapy of Moloney Sarcoma Virus-induced Tumors in Mice.  
Alexander Fefer.

2184 Lung Tumor Response in Strain A Mice as a Quantitative Bioassay of Carcinogenic Activity of Some Carbamates and Aziridines.  
M. B. Shimkin, R. Wieder, M. McDonough, L. Fishbein, and D. Swern.

2191 Warfarin Therapy as an Adjunct to the Surgical Treatment of Malignant Tumors in Mice.  
James J. Ryan, Alfred S. Ketcham, and Hilda Wexler.

2195 Studies on the Mechanism of Action of Anthramycin Methyl Ether, A New Antitumor Antibiotic.  

2206 Carcinogenesis in Rats by Aflatoxins B1, G1, and B2.  

2212 The Production of Hemangioendothelialsarcoma in Rats by Feeding 5-Acetamido-3-(5-nitro-2-furyl)-6H-1,2,4-oxadiazine.  

2219 Pathogenesis, Histology, and Transplantability of Urinary Bladder Carcinomas Induced in Albino Rats by Oral Administration of N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide.  

2229 Increased Transfer RNA Methylase Activity in a Liver Tumor from Chicks with Marek’s Disease.  
Lewis R. Mandel, Bruce Hacker, and T. A. Maag.

2232 The Effect of Nucleoproteins upon Amino Acid Incorporation into Protein in Walker 256 Cells.  

2237 Tumors of the Marmoset Produced by Rous Sarcoma Virus.  
Barnt M. Levy, A. Cecil Taylor, Suzanne Hampton, and George W. Thoma.

2249 Suppression of Experimental Allergic Encephalomyelitis by a NSC 82196, A New Imidazole Carboxamide Derivative.  


2256 Program.

2259 List of Participants.

2260 Program Committee.

2261 Introduction. H. George Mandel

2262 Clinical Cancer Chemotherapy Today.  
Management of Drug-refractory Malignancy and Toxicity.

Model Systems.
Silvio Garattini (Chairman), Howard E. Skipper, Daniel E. Bergsagel, and Chan H. Park.

Immunologic Aspects of Cancer Chemotherapy.
D. Bernard Amos (Chairman), E. Mihich, Edmund Klein, John F. Burke, David W. Weiss, Marc A. Lappé, and Richmond T. Prehn.

Design of More Selective Antitumor Agents.

General Discussion Session.
Abraham Goldin (Chairman).

Basis for Future Approaches.
H. George Mandel (Chairman), Charles Heidelberger, T. A. Connors, Gertrude B. Elion, Harris Busch, Wesley C. Starbuck, Joseph Leighton, Robert E. Handschumacher, Charles A. Nichol, and David P. Rail.

Summation of Symposium.
H. George Mandel and David P. Rail.

Books Received.

Special Announcement.

Announcements.

Errata.

Acknowledgment to Reviewers.

Index to Volume 29.

Contents of Volume 29, 1969.

Cover illustrations for 1969.

 COVER LEGEND


Jensen’s data gave firm evidences of a genuine transplantation of malignant tissues; the possibility of the transference of an “infective” principle could not be verified. In 1908 Jensen reported an inoculable rat sarcoma which became a standard tumor line in cancer laboratories throughout the world (Uebertragbare Rattensarkome. Z. Krebsforsch., 7: 45–54, 1909). His results and other contemporary contributions to tumor transplantation research were reviewed by V. A. Triolo in Cancer Res., 24: 4–27, 1964.
